testosterone and MI

there seems to be much more demand for testosterone (i assume promoted by advertising and men's magazines), even in inner city Boston.  there have been a couple of cautionary articles in the past year or so (small RCT in 2010 of testosterone gel in men with  decreased muscle function, stopped because of excess cardiovasc events; VA study of men>60yo most with CAD found increase in cardiovasc outcomes).  the open access journal PLOS ONE published an article today funded by the national cancer institute -- and not pharma (see testosterone and nonfatal MI pLos 2014, or DOI: 10.1371/journal.pone.0085805), a cohort study of 56K men prescribed testosterone therapy (TT) from a large health-care database (representing men from around the US) and looked at the incidence of MI in the 90 days following the initial prescription (earlier studies found excess cardiovasc risk occurred soon after starting TT). they compared this rate to 167K men men receiving phosphodiesterage-5 inhibitors (PDE5I, sildenafil/tadalafil), and compared MIs as a ratio of post-TT  to pre-TT, with MIs post-to-pre PDE5I). comparison to PDE5I was chosen since men with some similar issues are given TT or PDE5I, and PDE5I has no testosterone effects.  results:

    --MI ratio for men pos/pre TT: 1.36
    --MI ratio for men over age 65 was 2.19, but a non-significant 1.15 for PDE5I
    --MI ratio with TT varied with age, from .95 in those<55yo to 3.43 in those >75, with no trend with PDE5I
    --MI ratio for TT in men with prior history of heart disease was 2.9, but a nonsignificant 1.4 for PDE5I

so, this study adds to the concern about testosterone therapy.  there are important weaknesses, since they used a health care database (without knowledge of clinical indication for TT or data on testosterone levels), though a meta-analysis of small RCTs did not find an association with baseline testosterone levels. in addition, they chose a reasonable surrogate, by comparing TT with men on PDE5I, since there was at least a commonality between these groups around sexual function (though not around fatigue, muscle weakness, etc).  so, no firm conclusions, but a cautionary note....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more